Research ExplorerJournalsCANCER CHEMOTH PHARM Publications

CANCER CHEMOTH PHARM - Cancer chemotherapy and pharmacology

1 - 14 out of 14Page size: 50

Publications

  1. 2015

  2. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

    Machiels, J-P., Specenier, P., Krauß, J., Dietz, A., Kaminsky, M-C., Lalami, Y., Henke, M., Keilholz, U., Knecht, R., Skartved, N. J., Horak, I. D., Pamperin, P., Braun, S. & Gauler, T. C., 07.2015, In: CANCER CHEMOTH PHARM. 76, 1, p. 13-20 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. 2014

  4. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial

    Erhardt, A., Kolligs, F., Dollinger, M., Schott, E., Wege, H., Bitzer, M., Gog, C., Lammert, F., Schuchmann, M., Walter, C., Blondin, D., Ohmann, C. & Häussinger, D., 01.11.2014, In: CANCER CHEMOTH PHARM. 74, 5, p. 947-954 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. 2011

  6. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.

    Holweger, K., Lipp, H-P., Beijnen, J. H., Bokemeyer, C. & Hartmann, J. T., 2011, In: CANCER CHEMOTH PHARM. 68, 3, p. 693-701 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.

    Pelzer, U., Arnold, D., Reitzig, P., Herrenberger, J., Korsten, F. W., Kindler, M., Stieler, J., Dörken, B., Riess, H. & Oettle, H., 2011, In: CANCER CHEMOTH PHARM. 68, 5, p. 1173-1178 5.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. 2010

  9. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.

    Sehouli, J., Camara, O., Mahner, S., Bauknecht, T., Lichtenegger, W., Runnebaum, I., Look, K., Jänicke, F. & Oskay-Oezcelik, G., 2010, In: CANCER CHEMOTH PHARM. 66, 5, p. 861-868 5.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. 2009

  11. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

    Sehouli, J., Camara, O., Schmidt, M., Mahner, S., Seipelt, G., Otremba, B., Schmalfeldt, B., Tesch, H., Lorenz-Schlüter, C. & Oskay-Ozcelik, G., 2009, In: CANCER CHEMOTH PHARM. 64, 3, p. 585-591 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. 2003

  13. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis.

    Raedler, T. J., Jahn, H., Goedeken, B., Gescher, D. M., Kellner, M. & Wiedemann, K., 2003, In: CANCER CHEMOTH PHARM. 52, 6, p. 482-486 6.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. 2001

  15. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx.

    Bier, H., Hoffmann, T., Hauser, U., Wink, M., Ochler, M., Kovar, A., Müser, M. & Knecht, R., 2001, In: CANCER CHEMOTH PHARM. 47, 6, p. 519-524 6.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. 1998

  17. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.

    Erb, N., Harms, D. O. & Janka-Schaub, G., 1998, In: CANCER CHEMOTH PHARM. 42, 4, p. 266-272 4.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. 1993

  19. Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.

    Schaefer, A., Westendorf, J., Lingelbach, K., Schmidt, C. A., Mihalache, D. L., Reymann, A. & Marquardt, H., 1993, In: CANCER CHEMOTH PHARM. 31, 4, p. 301-307 4.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl.

    Reymann, A., Looft, G., Woermann, C., Dietel, M. & Erttmann, R., 1993, In: CANCER CHEMOTH PHARM. 32, 1, p. 25-30 1.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. 1989

  22. Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

    Bielack, S. S., Erttmann, R., Looft, G., Purfürst, C., Delling, G., Winkler, K. & Landbeck, G., 1989, In: CANCER CHEMOTH PHARM. 24, 6, p. 376-380 6.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. 1986

  24. A rapid chromatographic procedure for the determination of adriamycin, daunomycin and their 13-OH metabolites adriamycinol and daunomycinol.

    Erb, N., Erttmann, R. & Landbeck, G., 1986, In: CANCER CHEMOTH PHARM. 17, 1, p. 53-55 1.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  25. 1985

  26. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.

    Erttmann, R., Bielack, S. & Landbeck, G., 1985, In: CANCER CHEMOTH PHARM. 15, 2, p. 101-104 2.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review